Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
| Merck & Co. (NYSE: MRK) | Delayed: 141.82 +1.21 (0.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $140.61 | 52 Week High | $65.46 | |||
| Open | $140.22 | 52 Week Low | $47.97 | |||
| Day High | $142.69 | P/E | 96.48 | |||
| Day Low | $139.83 | EPS | $1.47 | |||
| Volume | 9,045,062 | |||||
